📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-27 14:57
570 analysed today
570
Today
133,459
All-time analysed
40,112
Positive
6,281
Negative
79,251
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
11 announcements match the current filters (relevance ≥ 5).
Bal Pharma Sets Sep 17, 2026 Record Date for Rs 1.20/Share (12%) Final Dividend
Bal Pharma Limited has fixed September 17, 2026, as the record date to determine shareholder eligibility for a final dividend of Rs 1.20 per equity share (12% on face value of Rs 10) for FY 2025-26. Subject to approval at the AGM, the dividend will be disbursed on or after September 24, 2026. At the current share price of Rs 84.0, this translates to an approximate dividend yield of 1.43%. The company also communicated TDS procedures and exemption guidelines for shareholders.
Confidence: HIGH
What changedBal Pharma formalized the record date and payment timelines for its FY26 final dividend of Rs 1.20 per share.
Why it mattersProvides payout certainty for eligible shareholders, translating to an annual dividend yield of ~1.43% on the current market price of Rs 84.0.
Dividend per share: Rs. 1.20Dividend percentage: 12%Record date: 17-Sep-2026Payment date: 24-Sep-2026Dividend yield on CMP: ~1.43%
📅 Short termThe stock is expected to trade ex-dividend shortly before the September 17, 2026 record date.
📈 Long termLimited; routine annual profit distribution in line with regular capital allocation.
Key Highlights
Final dividend fixed at Rs 1.20 per equity share (12% of face value Rs 10/-)
Record date determined as Thursday, September 17, 2026
Dividend payment scheduled on or after September 24, 2026
Nil TDS applies to resident individuals with valid PAN for dividend payouts up to Rs 10,000
👀 What to Watch
Shareholders seeking lower or nil TDS deduction should submit requisite declarations to the RTA before the record date, and ensure bank details and PAN are updated in demat accounts.
Bal Pharma Q1 Profit Jumps 443% to ₹1.14 Cr; Approves ₹9 Cr Philippines JV & ₹8.4 Cr Warrants
Bal Pharma reported a strong start to FY27 with Q1 revenue growing 34.5% YoY to ₹88.62 Cr and net profit surging 443% to ₹1.14 Cr. The board approved a strategic ₹9 Cr investment for a 65% stake in a new Joint Venture in the Philippines to target ASEAN markets. Additionally, the company is raising ₹8.4 Cr through the allotment of 10 lakh warrants to the promoter at ₹84 per warrant, with 25% of the amount already received. Management changes were also finalized, including the redesignation of Mr. Ravindra Kumar Kothari as a Whole-Time Director.
Confidence: HIGH
What changedThe company has reported a sharp recovery in quarterly earnings, initiated a major geographic expansion into the Philippines, and secured promoter-led funding.
Why it mattersThe Philippines JV represents a structural move to penetrate the ASEAN market, while the warrant allotment provides growth capital and strengthens the promoter's commitment to the business.
Q1 Revenue: ₹88.62 CrQ1 Net Profit: ₹1.14 CrJV Investment: ₹9 CrWarrant Issue Price: ₹84JV Investment vs Net Worth: ~8.6%Warrant Allotment vs Market Cap: ~5.8%
📅 Short termThe stock is likely to react positively to the strong YoY earnings growth and the promoter's capital infusion at a price close to the current market value.
📈 Long termThe entry into the Philippines and potential expansion into other ASEAN markets could diversify revenue streams and improve the scale of the formulation business over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in the new Philippines geography
- Equity dilution from warrant conversion
- High debt-to-equity ratio of 1.48
Key Highlights
Revenue from operations grew 34.5% YoY to ₹88.62 Cr in Q1 FY27 compared to ₹65.87 Cr in Q1 FY26.
Net profit increased to ₹1.14 Cr from ₹0.21 Cr in the same quarter last year, a 443% jump.
Approved a ₹9 Cr investment (approx. 8.6% of net worth) for a 65% stake in a new Philippines-based JV for pharmaceutical distribution.
Allotted 10,00,000 warrants to promoter Mr. Shailesh Siroya at ₹84 each, totaling ₹8.4 Cr (approx. 5.8% of market cap).
EPS improved significantly to ₹0.71 for the quarter from ₹0.13 in the year-ago period.
👀 What to Watch
Investors should monitor the execution timeline of the Philippines JV and the impact of the 5 new export formulation products on future margins. The promoter's warrant subscription at ₹84 (near current market price) is a positive signal of internal confidence.
Bal Pharma Q1 Revenue Up 34% YoY; Board Approves ₹9 Cr Philippines JV and ₹8.4 Cr Warrant Issue
Bal Pharma reported a strong 34.5% YoY revenue growth to ₹88.62 Cr for Q1 FY27, although net profit declined 68% sequentially to ₹1.14 Cr. The board approved a strategic ₹9 Cr investment (approx. 6.2% of market cap) to form a 65% owned Joint Venture in the Philippines for ASEAN market expansion. Additionally, the company allotted 10 lakh warrants to the promoter at ₹84 per share, raising an initial ₹2.1 Cr (25% of the total ₹8.4 Cr). Management changes were also finalized, with a new Whole-Time Director appointment effective October 2026.
Confidence: HIGH
What changedThe company has initiated a formal international expansion into the Philippines and secured a capital commitment from its promoter through a preferential warrant issue.
Why it mattersThe JV provides a structured path into the ASEAN pharmaceutical market, diversifying revenue beyond the competitive domestic API segment. The warrant issue at ₹84 (near the current market price of ₹90.5) signals promoter support for the company's growth plans.
Q1 FY27 Revenue: ₹88.62 CrYoY Revenue Growth: 34.5%JV Investment Amount: ₹9 CrJV Investment vs Market Cap: ~6.2%Warrant Issue Price: ₹84Q1 FY27 EPS: ₹0.71
📅 Short termThe strong YoY revenue growth and the news of international expansion are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe Philippines JV could be a structural growth driver if the company successfully navigates local regulatory approvals and scales its distribution in the ASEAN region.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High Debt-to-Equity ratio of 1.48
- Sequential decline in net profit (68% QoQ)
- Regulatory risks associated with international pharmaceutical registrations
Key Highlights
Revenue from operations grew 34.5% YoY to ₹88.62 Cr in Q1 FY27 compared to ₹65.87 Cr in Q1 FY26.
Net profit increased significantly YoY to ₹1.14 Cr from ₹0.21 Cr, though it fell from ₹3.60 Cr in the preceding March quarter.
Approved a ₹9 Cr investment for a 65% stake in a new Joint Venture in the Philippines to target ASEAN markets.
Allotted 1,000,000 warrants to Promoter Shailesh Siroya at ₹84 per warrant, totaling ₹8.40 Cr.
Received 25% of the warrant issue price (₹2.10 Cr), with the remaining 75% due within 18 months.
👀 What to Watch
Monitor the execution timeline of the Philippines JV and the impact of ASEAN market entry on margins. Investors should also track the conversion of promoter warrants, which will provide capital to manage the company's relatively high debt-to-equity ratio of 1.48.
10 Lakh Warrants to Promoters: Bal Pharma Shareholders Approve Preferential Issue
Shareholders of Bal Pharma have approved a special resolution to issue 1,000,000 warrants to the company's promoters on a preferential basis. The resolution passed with a significant majority, with 99.96% of the 81.59 lakh votes cast in favor. This capital infusion comes at a time when the company carries a debt of 154 Cr against a market cap of 139 Cr. The move signals promoter confidence and provides a path for equity-based funding to support the company's growth strategy in APIs and formulations.
Confidence: HIGH
What changedShareholders have officially authorized the company to proceed with a preferential warrant issue to promoters, following the initial proposal in July 2026.
Why it mattersThis represents a commitment of capital from the promoters, which is vital for a company with a high Debt-to-Equity ratio of 1.48. It provides the liquidity needed to pursue its target of 10.32% growth and expansion into regulated export markets.
Warrants to be issued: 10,00,000 unitsApproval Majority: 99.96%Potential Equity Dilution: ~6.28%Total Shares Outstanding: 1,59,20,872Debt-to-Equity Ratio: 1.48
📅 Short termThe successful passing of the resolution is likely to be viewed positively by the market as a sign of promoter support, potentially stabilizing the stock price in the near term.
📈 Long termIf the warrants are converted and funds are used to deleverage the balance sheet or fund the launch of the 5 new export formulations, it could improve the company's thin net profit margins (currently ~2%).
⚠ Risk flags
- Equity dilution for minority shareholders
- High debt levels (Rs 154 Cr) relative to market cap
- Pricing power limited by Chinese competition in API segment
Key Highlights
Approval granted for the issuance of 10,00,000 warrants to the Promoter group on a preferential basis.
Resolution passed with 99.96% (81,55,799 votes) in favor and only 0.04% (3,264 votes) against.
Total voting participation represented 51.25% of the company's total equity capital of 1,59,20,872 shares.
The remote e-voting process concluded on August 08, 2026, with results declared on August 10, 2026.
Promoter and Promoter Group voted 100% in favor of the resolution for their 80,97,182 shares.
👀 What to Watch
Investors should monitor the announcement of the warrant issue price and the specific timeline for the infusion of funds. The conversion of these warrants will result in a roughly 6.3% equity dilution, so tracking how the proceeds are used (debt reduction vs. capex) is critical.
₹8.40 Cr Fundraise: Bal Pharma Revises Warrant Price and Details Greenfield API Project
Bal Pharma has issued a corrigendum to its July 9 postal ballot regarding a preferential issue of 10 lakh convertible warrants to its promoter, Mr. Shailesh Siroya. The issue price has been revised upward from ₹81 to ₹84 per warrant, increasing the total fundraise to ₹8.40 Cr (approx. 6% of market cap). The proceeds are specifically earmarked for a greenfield API manufacturing facility in Yadgiri, Karnataka, for which 5 acres of land have already been acquired. This revision follows regulatory clarifications from stock exchanges regarding valuation and pricing compliance.
Confidence: HIGH
What changedThe company increased the preferential issue price for promoter warrants to ₹84 and provided specific details regarding the greenfield API expansion project in Karnataka.
Why it mattersThe fundraise supports vertical integration through a new API facility, which is critical for a company with a 10.3% OPM facing pricing pressure from Chinese API imports.
Revised Issue Price: ₹84Total Fundraise: ₹8.40 CrFundraise vs Market Cap: ~5.96%Land Acquired for Project: 5 acresUpfront Payment (25%): ₹2.10 Cr
📅 Short termThe upward revision in the issue price and clarity on the use of proceeds for a specific expansion project are likely to be viewed as positive governance and growth signals.
📈 Long termThe greenfield API facility could structurally improve margins and competitiveness, though the company's high debt-to-equity ratio of 1.48 remains a long-term monitoring point.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High debt-to-equity ratio (1.48)
- Execution risk associated with greenfield manufacturing projects
- Limited pricing power in the competitive API segment
Key Highlights
Issue price revised upward from ₹81 to ₹84 per warrant, a 3.7% increase following regulatory feedback
Total fundraise amount increased to ₹8.40 Cr from the previously planned ₹8.10 Cr
Greenfield API project details disclosed: 5 acres of land acquired in Yadgiri, Karnataka, with environmental approvals in place
Independent valuation report set the fair value at ₹83.869 per share using the market approach
Promoter to pay 25% (₹21 per warrant) upfront, with the remaining 75% (₹63) due upon conversion within 18 months
👀 What to Watch
Investors should monitor the postal ballot voting results ending August 8, 2026, and watch for subsequent updates on the construction timeline of the Yadgiri API facility.
10 Lakh Warrants to Promoter at Rs 81: Bal Pharma Seeks Shareholder Approval
Bal Pharma is seeking shareholder approval via postal ballot to issue 10,00,000 warrants to its promoter, Mr. Shailesh Siroya, at a price of Rs 81 per warrant. The total capital infusion amounts to Rs 8.1 crore, representing approximately 7.8% of the company's current net worth of Rs 104 Cr. The voting period for shareholders is scheduled from July 10 to August 08, 2026. While the amount is relatively small compared to TTM revenue of Rs 311 Cr, it indicates continued promoter commitment to the business.
Confidence: HIGH
What changedThe company has moved from a board-level proposal to a formal shareholder approval process for a preferential warrant issue to the promoter.
Why it mattersThis represents a direct capital infusion by the promoter, signaling confidence in the company's turnaround or growth prospects, especially given the recent quarterly PAT growth (Rs 3.6 Cr in Mar 2026 vs Rs 0.2 Cr in Jun 2025).
Warrants to be issued: 10,00,000Issue Price: Rs 81Total Issue Value: Rs 8.1 CrIssue vs Net Worth: ~7.8%Issue vs TTM Revenue: ~2.6%
📅 Short termThe market may view the promoter's willingness to subscribe at Rs 81 as a benchmark for the stock's near-term floor, depending on where the current market price sits.
📈 Long termThe fundraise is modest and unlikely to significantly deleverage the company (Debt is Rs 154 Cr). Long-term value depends on the execution of the API and export formulation growth strategy.
⚠ Risk flags
- Minor equity dilution for non-promoter shareholders
- High Debt-to-Equity ratio (1.48) remains a concern
Key Highlights
Proposed issue of 10,00,000 warrants convertible into equity shares to the Promoter.
Warrants priced at Rs 81 per unit, totaling a fundraise of Rs 8.1 crore.
Remote e-voting period commences on July 10, 2026, and ends on August 08, 2026.
Cut-off date for determining shareholder voting eligibility was July 03, 2026.
Results of the postal ballot to be announced on or before August 11, 2026.
👀 What to Watch
Investors should monitor the voting results on August 11, 2026, and the subsequent timeline for warrant conversion. The capital infusion is small, so focus should remain on the company's ability to manage its high Debt/Equity ratio of 1.48.
Bal Pharma Recommends ₹1.20 Dividend; FY26 Revenue Grows to ₹310.80 Crore
Bal Pharma Limited has recommended a final dividend of ₹1.20 per equity share (12%) for the financial year ended March 31, 2026. The company reported a steady increase in standalone annual revenue, reaching ₹310.80 crore compared to ₹302.50 crore in the previous fiscal year. Beyond financials, the board approved a preferential issue of 10 lakh warrants to promoters and the grant of 5 lakh ESOPs to employees, signaling internal confidence and growth alignment.
Key Highlights
Recommended a final dividend of ₹1.20 per equity share (12% on face value of ₹10).
Standalone revenue from operations for FY26 rose to ₹310.80 crore from ₹302.50 crore in FY25.
Approved preferential issue of 10,00,000 warrants to promoters, subject to shareholder approval via postal ballot.
Granted 5,00,000 stock options to employees under the 'Bal Pharma Limited — Employee Stock Option Plan-2025'.
Appointed Mr. Shreepada ML as Company Secretary and Compliance Officer effective May 27, 2026.
👀 What to Watch
Investors should monitor the upcoming Annual General Meeting for dividend approval and the postal ballot for the warrant issue. The steady revenue growth and promoter warrant subscription are positive indicators of long-term stability.
Bal Pharma FY26 Revenue Hits ₹310.8 Cr; Recommends ₹1.20 Dividend and Promoter Warrant Issue
Bal Pharma Limited reported a steady financial performance for FY26, with standalone annual revenue from operations rising to ₹310.80 crore from ₹302.50 crore in the previous year. The board has recommended a dividend of ₹1.20 per share (12%), rewarding shareholders for the year's performance. In a move showing promoter confidence, the company approved the preferential issue of 1,000,000 warrants to the promoter group. Additionally, the company is incentivizing staff through a new ESOP plan involving 500,000 stock options.
Key Highlights
Standalone annual revenue from operations grew to ₹31,079.70 lakhs in FY26 vs ₹30,249.64 lakhs in FY25.
Recommended a dividend of ₹1.20 per equity share (12% on face value of ₹10).
Approved preferential issue of 1,000,000 warrants to promoters, subject to shareholder approval.
Granted 500,000 stock options to employees under the new Employee Stock Option Plan-2025.
Appointed Mr. Shreepada ML as Company Secretary and Compliance Officer effective May 27, 2026.
👀 What to Watch
Investors should take note of the promoter warrant issue as a positive signal of long-term commitment. The steady revenue growth and dividend yield provide a stable outlook, though the conversion price of warrants should be monitored.
Bal Pharma FY26 Revenue at ₹310.8 Cr; Recommends ₹1.20 Dividend & Promoter Warrant Issue
Bal Pharma reported a steady annual performance for FY26 with revenue from operations reaching ₹310.80 crore, up from ₹302.50 crore in the previous fiscal. The board has recommended a dividend of ₹1.20 per share (12%) and approved a preferential issue of 10 lakh warrants to promoters, signaling strong internal confidence. Additionally, the company is focusing on talent retention by granting 5 lakh ESOPs. The appointment of a new Company Secretary and the unmodified audit opinion further suggest stable corporate governance.
Key Highlights
Annual revenue from operations grew to ₹310.80 crore in FY26 from ₹302.50 crore in FY25.
Recommended a dividend of ₹1.20 per equity share (12% of face value).
Approved preferential issue of 10,00,000 warrants to promoters to raise capital.
Granted 5,00,000 stock options to employees under the ESOP-2025 plan.
Q4 FY26 revenue stood at ₹83.92 crore compared to ₹81.78 crore in the same quarter last year.
👀 What to Watch
The promoter warrant issue and dividend payout are positive signals for long-term investors; however, one should monitor the conversion price of warrants for potential dilution. The marginal revenue growth suggests a stable business profile, making it a hold for those seeking steady returns.
Bal Pharma to Consider Fund Raising via Preferential Warrants to Promoters on May 27
Bal Pharma Limited has issued an addendum to its board meeting notice scheduled for May 27, 2026. The board will now consider a proposal for fund raising through the issuance of preferential warrants specifically to the company's promoters. This move follows the initial meeting notice dated May 18, 2026, and indicates a potential capital infusion. Such actions often signal promoter confidence in the company's long-term growth prospects.
Key Highlights
Board meeting scheduled for May 27, 2026, to consider new fund raising agenda.
Proposal involves the issuance of preferential warrants specifically to the promoter group.
The announcement serves as an addendum to the previous intimation made on May 18, 2026.
The capital infusion is intended to strengthen the company's financial position.
👀 What to Watch
Investors should watch for the board's decision on May 27 regarding the quantum of funds and the warrant pricing. Promoter-led funding is generally a positive signal for minority shareholders as it aligns interests and provides growth capital.
Bal Pharma Q3 FY26 Consolidated PAT Jumps 245% YoY to ₹1.79 Cr; Revenue Up 20%
Bal Pharma reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 19.8% YoY to ₹87.69 crore. The bottom line saw significant expansion, with net profit surging 245% YoY to ₹1.79 crore compared to ₹0.52 crore in the same quarter last year. On a sequential basis, revenue grew by 18.4% and profit more than doubled from ₹0.72 crore in Q2 FY26. The company continues to operate in a single segment, Pharmaceuticals, and maintained an unmodified audit opinion.
Key Highlights
Consolidated Revenue from operations increased by 19.8% YoY to ₹8,768.97 Lakhs.
Net Profit for the quarter surged 245% YoY to ₹179.06 Lakhs from ₹51.79 Lakhs.
Earnings Per Share (EPS) improved significantly to ₹1.12 from ₹0.33 in the year-ago period.
Profit Before Tax (PBT) grew by 216% YoY, reaching ₹179.05 Lakhs.
Nine-month (9M FY26) consolidated net profit stands at ₹271.63 Lakhs compared to ₹181.82 Lakhs YoY.
👀 What to Watch
The sharp jump in profitability and steady double-digit revenue growth are positive indicators for this small-cap pharma player. Investors should monitor the sustainability of these improved margins in the upcoming quarters.
